Astria Therapeutics Inc. (ATXS)
6.63
-0.51 (-7.14%)
At close: Mar 13, 2025, 11:26 AM
Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Astria Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 25, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Jill C. Milne Ph.D. |
Contact Details
Address: 100 High Street Boston, Massachusetts United States | |
| Website | https://www.astriatx.com |
Stock Details
| Ticker Symbol | ATXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001454789 |
| CUSIP Number | 04635X102 |
| ISIN Number | US04635X1028 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Benjamin S. Harshbarger J.D. | Chief Legal Officer |
| Andrea L. Matthews | Chief Business Officer |
| Andrew A. Komjathy | Chief Commercial Officer |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
| John Ruesch | Senior Vice President of Pharmaceutical Sciences & Technical Operations |
| Keri McGrail | Chief Human Resources Officer |
| Rafif Dagher | Senior Vice President and Head of Discovery, Nonclinical Development & Translational Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 28, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 07, 2025 | SCHEDULE 13G | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |